A Clinical Trial for People with Cystic Fibrosis (CF)
Who Have Specific Mutations in the CFTR Gene, Which Are the Cause of CF
This clinical trial is exploring a potential new inhaled messenger RNA (mRNA) treatment called RCT2100 that may improve the function of the CFTR protein in the lungs, getting at the root cause of lung health rather than just controlling symptoms.
Here, you will find more information about the trial, investigative inhaled therapy, and how you, or someone you know, can participate.
About Cystic Fibrosis
CF is a progressive genetic condition that causes persistent lung infections and respiratory failure. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and impacts approximately 105,000 people worldwide.
The absence or dysfunction of the CFTR protein results in a defect in airway hydration, which leads to excessive mucus buildup in the lungs. It also creates a mucociliary clearance defect, recurrent infections, inflammation, respiratory failure, and other complications.
Despite the availability of CFTR modulators that work for 90% of people with CF, many will not be able to take the medication due to side effects, lack of response, or other reasons. About 10% of the CF community have genetic mutations that do not benefit from these therapeutics.
CF impacts approximately 105,000 people worldwide. 90% have responsive genotypes to CFTR modulators, and 10% (10,500 people) do not.
Why this Trial is Important
No CFTR modulator therapies are currently approved to treat individuals with certain mutations in the CFTR gene because these mutations prevent the production of any CFTR protein.
Without CFTR protein, there is nothing available for the therapy to correct. This trial aims to find out whether the investigative inhaled therapy is safe and may work as a potential new treatment option for people with CF who are not eligible for, or are eligible but not currently taking, CFTR modulator therapy.
To learn more, contact:
How the Clinical Trial Medicine Works
ReCode is developing RCT2100, an investigative inhaled therapy for cystic fibrosis (CF) based on messenger RNA (mRNA). This treatment is designed to deliver CFTR mRNA directly to target cells in the lungs, instructing them to produce a functional version of the CFTR protein.
Unlike current CFTR modulators that work on existing defective proteins by either correcting or potentiating that protein, RCT2100 is designed to allow the cells to make new functional CFTR protein.
By providing CFTR mRNA to individuals with CF who are missing this protein, the therapy aims to address the underlying cause of the condition, potentially improving CFTR protein function in the lungs rather than just managing symptoms.
How the Clinical Trial Medicine is Given
The investigative medicine, RCT2100, will be given using a nebuliser — a medical device that converts liquid medication into a mist for inhalation.
1 Screening
There will be a 2–4-hour clinic visit to determine your eligibility to participate and an opportunity for you to ask any questions to see if this trial is right for you.
2 Treatment
If you are eligible, you will receive inhaled doses of RCT2100.
3 Follow-up
After your last dose, there will be a 24-week follow-up period, which includes a final outpatient visit.
Tests and procedures
Throughout the trial, you will have certain exams and tests, including:
Physical Exam
Vital Signs Measurement
A non-invasive test to record the heart’s electrical activity
Chest X-Ray
(if you have not had one within six months)
A non-invasive test that measures oxygen in the blood
A non-invasive test to measure how much and how fast you can move air into and out of your lungs and how well your lungs are exchanging gases
Blood and Urine Tests
Full details will be provided for your consideration prior to completing and signing an informed consent which confirms you fully understand the process and implications of taking part in the trial.
Eligibility
Who Can Participate
- Those who are 18-65 years old
- Those with a diagnosis of CF
- People with CF not eligible for treatment with CFTR modulators based on having mutations of the CFTR gene or people with CF who are eligible, but not able to tolerate CFTR modulators
- Anyone with a forced expiratory volume (FEV1) greater than 40% predicted
- Those willing to use contraception
Who Cannot Participate
- Those who are pregnant or breastfeeding
- Anyone who has received treatment with a CFTR modulator in the last 12 weeks
- Those who have had a CF pulmonary exacerbation in the last 4 weeks
- Anyone with a lung infection caused by organisms including B. cenocepacia, B. dolosa or M. abscessus
- An oxygen saturation <94% on room air
FAQs
What is a clinical trial?
A clinical trial is a carefully designed investigation to assess the safety, effectiveness, and potential benefits of medical treatments, interventions, or procedures in humans. These studies are essential for advancing medical knowledge and improving patient care.
Participants in a clinical trial may receive new investigative treatments and are closely monitored to observe their responses and outcomes. The studies follow strict ethical guidelines and regulatory requirements to ensure the safety and rights of participants.
By participating in a clinical trial, people with CF contribute to developing new medical therapies and may gain access to innovative treatments that might not yet be widely available.
Where will this trial take place?
Many trial sites are enrolling in the U.S. and U.K., as well as in France and the Netherlands. Click here to find a list of all available trial sites.
How much of my time will this clinical trial take up?
If you are eligible and decide to participate in the trial, a research team will share more information about the time expected from you during the trial.
There are three parts to the trial:
- Screening period: involves a 2–4-hour clinic visit to determine your eligibility to participate and an opportunity for you to ask any questions to see if this study is right for you.
- Treatment period: will take 4 weeks where you will receive RCT2100
- Follow-up period: will take 24 weeks.
If you participate, you can expect to be in the trial for about 28 weeks (~7 months).
Will I receive compensation for participating in the trial?
Will I be responsible for the cost of travel and other items to participate?
There will be no cost for you to participate. ReCode will pay for all required tests, procedures, travel, and accommodations.
What are the risks of participating in a clinical trial?
Participating may involve some potential risks, which may occur from the investigative trial medicine or the tests.
You will receive an informed consent form describing the full risks involved before agreeing to participate in the trial.
The research team will also discuss risks with you and answer any questions that you may have about the trial.
What are the benefits of participating in a clinical trial?
Participating in a clinical research study for CF may contribute to the advancement of medical science, helping to develop new treatments for CF that can benefit others in the future.
It is difficult for me to travel to the trial site for dosing up to three times a week. Can I still participate?
With the research team’s approval, this trial offers a home visit option. This option allows for dosing at your home, carried out by a research nurse trained to administer RCT2100 after you receive your first two doses. The research nurse will arrive one hour before dosing and remain at your home one-hour post-dose.
Can I change my mind regarding participation?
The withdrawal process will be discussed in detail at the initial consultation.
Who will be overseeing my care during the trial?
The research team at the trial site will oversee your care during the trial. If the CF [doctor] consultant leading the study is not a member of your usual CF Specialist Team, they will closely liaise with them to oversee your care during your participation period.
They will work with the trial team to ensure the clinical trial does not conflict with any medications or treatments you may currently be receiving.
Will I be excluded from participation in other trials?
Participants in the RCT2100-101 trial should not be excluded from other trials after an appropriate wash-out period (as defined in the other study protocols for the trials participants may be interested in).
Does ReCode have a privacy policy?
Please refer to the ReCode privacy policy here.
